Antidepressants Trial in Parkinson's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

January 23, 2023

Study Completion Date

April 30, 2023

Conditions
DepressionParkinson Disease
Interventions
DRUG

Nortriptyline

A medication used to treat conditions such as depression

DRUG

Escitalopram

A medication used to treat conditions such as depression

DRUG

Placebo

Lactose and magnesium stearate tablet to be used as a placebo.

Trial Locations (1)

NW3 2QG

Royal Free London NHS Foundation Trust, London

All Listed Sponsors
collaborator

London North West Healthcare NHS Trust

OTHER

collaborator

King's College London

OTHER

collaborator

University Hospital Plymouth NHS Trust

OTHER

collaborator

NHS Lothian

OTHER_GOV

lead

University College, London

OTHER

NCT03652870 - Antidepressants Trial in Parkinson's Disease | Biotech Hunter | Biotech Hunter